Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct;31(10):1004-1012.
doi: 10.1016/j.nmd.2021.08.003.

X-linked myotubular myopathy

Affiliations
Free article
Review

X-linked myotubular myopathy

Michael W Lawlor et al. Neuromuscul Disord. 2021 Oct.
Free article

Abstract

X-linked myotubular myopathy (XLMTM) is a severe congenital muscle disease caused by mutation in the MTM1 gene. MTM1 encodes myotubularin (MTM1), an endosomal phosphatase that acts to dephosphorylate key second messenger lipids PI3P and PI3,5P2. XLMTM is clinically characterized by profound muscle weakness and associated with multiple disabilities (including ventilator and wheelchair dependence) and early death in most affected individuals. The disease is classically defined by characteristic changes observed on muscle biopsy, including centrally located nuclei, myofiber hypotrophy, and organelle disorganization. In this review, we highlight the clinical and pathologic features of the disease, present concepts related to disease pathomechanisms, and present recent advances in therapy development.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest MWL is, or has recently been, a member of advisory boards for Solid Biosciences, Taysha Therapeutics, Astellas Gene Therapies (formerly Audentes Therapeutics), and Ichorion Therapeutics. MWL is also a consultant for Astellas Gene Therapies (formerly Audentes Therapeutics), Encoded Therapeutics, Modis Therapeutics, Lacerta Therapeutics, Dynacure, AGADA Biosciences, Affinia Therapeutics, and Biomarin. MWL receives research support from Astellas Gene Therapies, Solid Biosciences, Kate Therapeutics, and Prothelia. JJD is a scientific and medical advisor for Kate Therapeutics and Dynacure, is a site PI for the ASPIRO trial, and has received research support from Astellas and Dynacure.

Similar articles

Cited by

Publication types

Substances

Grants and funding

LinkOut - more resources